Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

BACKGROUND: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Noro, Rintaro, Gemma, Akihiko, Kosaihira, Seiji, Kokubo, Yutaka, Chen, Mingwei, Seike, Masahiro, Kataoka, Kiyoko, Matsuda, Kuniko, Okano, Tetsuya, Minegishi, Yuji, Yoshimura, Akinobu, Kudoh, Shoji
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2006
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1698934/
https://ncbi.nlm.nih.gov/pubmed/17150102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-277
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados